European regulators approve new Parkinson's treatment and reverse Rett syndrome drug decision, while safety concerns prompt reviews of tuberculosis and autoimmune medications.

The EMA approved a new dual-release formulation combining levodopa and carbidopa to treat moderate-to-severe motor fluctuations in Parkinson's disease patients, offering improved symptom management through immediate and sustained drug release.

The EMA reversed its previous decision and granted marketing authorization for trofinetide, marking the world's first drug specifically approved to treat Rett syndrome, a rare neurological disorder affecting children.

The EMA revoked approval for Tavneos, an autoimmune disease drug, after determining new data showed the risks of treating active granulomatosis with polyangiitis no longer justify the benefits.

European regulators launched a review of Rifadin syrup, a tuberculosis medication, following carcinogen safety concerns raised by the Dutch medicines agency, potentially affecting patient treatment options.

uniQure's one-time gene therapy AMT-130 for Huntington's disease faces regulatory challenges, with the company potentially seeking UK approval first while negotiating with the FDA over additional sham-controlled trial requirements.

Clinical trial data support the use of Pfizer's Paxlovid antiviral at current dosing levels for high-risk children aged 6 years and older with mild-to-moderate COVID-19, achieving effective blood concentrations.

Home-based human papillomavirus screening for cervical cancer shows modest uptake rates in diverse community settings, suggesting barriers remain to expanding this preventive screening approach.

New data from EULAR 2026 reveal that one-third of rheumatic disease patients experience severe, unresolved chronic pain 15 years after diagnosis, exposing significant gaps in current anti-inflammatory treatment protocols.